OverviewThe mission of continuing education at Evolve Medical Education LLC (Evolve) is to develop educational programs in a variety of learning formats. These programs are based on the outcomes of needs assessments, current trends, clinical data, and the latest technology that impacts health care practitioners, which will lead to the development of strategies to enhance clinician knowledge, competence, close professional practice gaps, improve provider performance in patient care, implement practice-based learning and improvement, professionalism, and systems-based practice. |
Glaucoma Treatments in 2021: Personalizing Patient Needs
This continuing medical education (CE/CME) activity captures content from a roundtable in August.
Activity Description
Based on a roundtable held in August, this supplement summarizes a discussion of the mechanisms of actions and challenges with currently available and novel therapeutics as well as how to personalize glaucoma treatments.
Target Audience
This certified CME/CE activity is ...
|
|
Individualizing Glaucoma Treatment: Understanding How to Utilize Traditional and Novel Agents
Join Nathan M. Radcliffe, MD, and Justin Schweitzer, OD, FAAO, as they discuss the ways in which novel therapeutics may help to overcome the challenges and limitations associated with currently available pharmacologic treatment options for ocular hypertension and primary open-angle glaucoma.
|
|
Neurotrophic Keratitis: Old Problem, New Solutions
Eye care providers may not understand what neurotrophic keratitis is or how it differs from other corneal diseases. In addition; eye care practitioners may be unaware of treatments in development, or the already approved treatments for neurotrophic keratitis. They also may not understand the mechanism of action of these newer treatments.
|
|
Putting Patients First: Best Practices for Neurotrophic Keratitis Diagnosis and Treatment
This previously recorded satellite symposium features an engaging presentation on the potential causes of neurotrophic keratitis, how to differentiate it from similar diseases, and when referrals may be necessary. Treatment options will also be discussed, including the mechanisms of action of newer therapies and when they should be introduced.
Case discussions and audience question-and-answer...
|
|
Recognition and Referral: Best Practices for Managing Patients with GA
Patients with advanced dry age-related macular degeneration can present with geographic atrophy (GA), a disease that is progressive and increases with age. Although there is no treatment approved by the FDA that halts or reverses GA, a number of drugs in the pipeline are designed to address GA progression, hoping to succeed where previous drug candidates failed. This series of regional, interact...
|